According to a new Pharmaceutical Research and Manufacturers of America (PhRMA) report, U.S. biopharmaceutical companies are currently developing 465 new medicines that target 10 leading chronic conditions affecting those ages 65 and older. Among the medicines, which are either in human clinical trials or under U.S. Food and Drug Administration review, are treatments for diabetes, rheumatoid arthritis and osteoarthritis, Alzheimer’s disease, heart failure, and chronic obstructive pulmonary disease.